359 related articles for article (PubMed ID: 29383608)
21. AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.
Schmitz KJ; Sotiropoulos GC; Baba HA; Schmid KW; Müller D; Paul A; Auer T; Gamerith G; Loeffler-Ragg J
Liver Int; 2011 Jul; 31(6):810-6. PubMed ID: 21645211
[TBL] [Abstract][Full Text] [Related]
22. Clinical value of AKR1B10 in hepatocellular carcinoma: A systematic review and meta-analysis.
Wang Z; Pei Y; Li W; Zhang J; Liu J
PLoS One; 2022; 17(12):e0279591. PubMed ID: 36584078
[TBL] [Abstract][Full Text] [Related]
23. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Ebert B; Kisiela M; Wsól V; Maser E
Chem Biol Interact; 2011 May; 191(1-3):239-49. PubMed ID: 21215737
[TBL] [Abstract][Full Text] [Related]
24. [Aldo-keto reductase family 1 B10 participates in the regulation of hepatoma cell cycle through p27/p-Rb signaling pathway].
Geng N; Jin YY; Zhu SX; Li YR; Zheng LY; Zhu WJ; Li YW; Han C; Dou XG; Bai H
Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):861-867. PubMed ID: 33105932
[No Abstract] [Full Text] [Related]
25. Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma.
Xie C; Ye X; Zeng L; Zeng X; Cao D
J Gastroenterol; 2023 Oct; 58(10):1030-1042. PubMed ID: 37500927
[TBL] [Abstract][Full Text] [Related]
26. Genome-wide and differential proteomic analysis of hepatitis B virus and aflatoxin B1 related hepatocellular carcinoma in Guangxi, China.
Qi LN; Li LQ; Chen YY; Chen ZH; Bai T; Xiang BD; Qin X; Xiao KY; Peng MH; Liu ZM; Liu TW; Qin X; Li S; Han ZG; Mo ZN; Santella RM; Winkler CA; O'Brien SJ; Peng T
PLoS One; 2013; 8(12):e83465. PubMed ID: 24391771
[TBL] [Abstract][Full Text] [Related]
27. Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
Matkowskyj KA; Bai H; Liao J; Zhang W; Li H; Rao S; Omary R; Yang GY
Hum Pathol; 2014 Apr; 45(4):834-43. PubMed ID: 24656094
[TBL] [Abstract][Full Text] [Related]
28. Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
Nishinaka T; Miura T; Sakou M; Hidaka C; Sasaoka C; Okamura A; Okamoto A; Terada T
Chem Biol Interact; 2015 Jun; 234():274-81. PubMed ID: 25463304
[TBL] [Abstract][Full Text] [Related]
29. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Yan R; Zu X; Ma J; Liu Z; Adeyanju M; Cao D
Int J Cancer; 2007 Nov; 121(10):2301-6. PubMed ID: 17597105
[TBL] [Abstract][Full Text] [Related]
30. Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication.
Murata A; Genda T; Ichida T; Amano N; Sato S; Tsuzura H; Sato S; Narita Y; Kanemitsu Y; Shimada Y; Hirano K; Iijima K; Wada R; Nagahara A; Watanabe S
World J Gastroenterol; 2016 Sep; 22(33):7569-78. PubMed ID: 27672277
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of an aldo-keto reductase gene signature with prognostic significance in colon cancer via activation of epithelial to mesenchymal transition and the p70S6K pathway.
Demirkol Canlı S; Seza EG; Sheraj I; Gömçeli I; Turhan N; Carberry S; Prehn JHM; Güre AO; Banerjee S
Carcinogenesis; 2020 Sep; 41(9):1219-1228. PubMed ID: 32628753
[TBL] [Abstract][Full Text] [Related]
32. Molecular mechanisms of nano-selenium in mitigating hepatocellular carcinoma induced by N-nitrosodiethylamine (NDEA) in rats.
Ahmed HH; Khalil WK; Hamza AH
Toxicol Mech Methods; 2014 Dec; 24(8):593-602. PubMed ID: 25156538
[TBL] [Abstract][Full Text] [Related]
33. A therapeutic method for the direct reprogramming of human liver cancer cells with only chemicals.
Moriguchi H; Zhang Y; Mihara M; Sato C
Sci Rep; 2012; 2():280. PubMed ID: 22355790
[TBL] [Abstract][Full Text] [Related]
34. Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Chung YT; Matkowskyj KA; Li H; Bai H; Zhang W; Tsao MS; Liao J; Yang GY
Mod Pathol; 2012 May; 25(5):758-66. PubMed ID: 22222635
[TBL] [Abstract][Full Text] [Related]
35. Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma.
Dai T; Ye L; Yu H; Li K; Li J; Liu R; Lu X; Deng M; Li R; Liu W; Yang Y; Wang G
J Hepatocell Carcinoma; 2021; 8():997-1021. PubMed ID: 34513744
[TBL] [Abstract][Full Text] [Related]
36. Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer.
Taskoparan B; Seza EG; Demirkol S; Tuncer S; Stefek M; Gure AO; Banerjee S
Cell Oncol (Dordr); 2017 Dec; 40(6):563-578. PubMed ID: 28929377
[TBL] [Abstract][Full Text] [Related]
37. E2F1-mediated AUF1 upregulation promotes HCC development and enhances drug resistance via stabilization of AKR1B10.
Zhang T; Guan G; Zhang J; Zheng H; Li D; Wang W; Lu F; Chen X
Cancer Sci; 2022 Apr; 113(4):1154-1167. PubMed ID: 35178834
[TBL] [Abstract][Full Text] [Related]
38. Engineering aldo-keto reductase 1B10 to mimic the distinct 1B15 topology and specificity towards inhibitors and substrates, including retinoids and steroids.
Giménez-Dejoz J; Weber S; Fernández-Pardo Á; Möller G; Adamski J; Porté S; Parés X; Farrés J
Chem Biol Interact; 2019 Jul; 307():186-194. PubMed ID: 31028727
[TBL] [Abstract][Full Text] [Related]
39. Murine aldo-keto reductase family 1 subfamily B: identification of AKR1B8 as an ortholog of human AKR1B10.
Joshi A; Rajput S; Wang C; Ma J; Cao D
Biol Chem; 2010 Dec; 391(12):1371-8. PubMed ID: 21087085
[TBL] [Abstract][Full Text] [Related]
40. Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).
Li H; Yang AL; Chung YT; Zhang W; Liao J; Yang GY
Carcinogenesis; 2013 Sep; 34(9):2090-8. PubMed ID: 23689354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
